Amlodipine
- Generic Name
- Amlodipine
- Brand Names
- Amlobenz, Azor, Caduet, Dafiro, Exforge, Exforge Hct, Katerzia, Lotrel, Norliqva, Norvasc, Prestalia, Tribenzor, Twynsta, Viacoram
- Drug Type
- Small Molecule
- Chemical Formula
- C20H25ClN2O5
- CAS Number
- 88150-42-9
- Unique Ingredient Identifier
- 1J444QC288
- Background
Amlodipine, initially approved by the FDA in 1987, is a popular antihypertensive drug belonging to the group of drugs called dihydropyridine calcium channel blockers. Due to their selectivity for the peripheral blood vessels, dihydropyridine calcium channel blockers are associated with a lower incidence of myocardial depression and cardiac conduction abnormalities than other calcium channel blockers .
Amlodipine is commonly used in the treatment of high blood pressure and angina. Amlodipine has antioxidant properties and an ability to enhance the production of nitric oxide (NO), an important vasodilator that decreases blood pressure . The option for single daily dosing of amlodipine is an attractive feature of this drug .
- Indication
Amlodipine may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of the following conditions :
• Hypertension
• Coronary artery disease
• Chronic stable angina
• Vasospastic angina (Prinzmetal’s or Variant angina)
• Angiographically documented coronary artery disease in patients without heart failure or an ejection fraction < 40%
- Associated Conditions
- Cardiovascular Events, Chronic Stable Angina Pectoris, Coronary Artery Disease (CAD), Homozygous Familial Hypercholesterolaemia (HoFH), Hypertension, Hypertension, Essential Hypertension, Mixed Dyslipidemias, Primary Hypercholesterolemia, Vasospastic Angina
- Associated Therapies
- -
Trial Comparing Metabolic Effects of Telmisartan and Amlodipine on Hypertensive Patients With Obesity and Diabetes
- First Posted Date
- 2009-02-19
- Last Posted Date
- 2013-12-17
- Lead Sponsor
- Third Military Medical University
- Target Recruit Count
- 120
- Registration Number
- NCT00847262
- Locations
- 🇨🇳
The third hospital affiliated to the Third Military Medical University, Chongqing, China
Amlodipine 10 mg Tablets Under Fed Conditions
- First Posted Date
- 2009-02-11
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 28
- Registration Number
- NCT00841815
- Locations
- 🇨🇦
Biovail Contract Research, Toronto, Ontario, Canada
Amlodipine 10 mg Tablets Under Fasting Conditions
- First Posted Date
- 2009-02-11
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 28
- Registration Number
- NCT00841542
- Locations
- 🇨🇦
Biovail Contract Research, Toronto, Ontario, Canada
A Study of the Effects of Eplerenone and Amlodipine on Blood Pressure and Basal Metabolic Rate in Obese Hypertensives
- Conditions
- Interventions
- First Posted Date
- 2009-01-19
- Last Posted Date
- 2018-05-29
- Lead Sponsor
- University of Mississippi Medical Center
- Target Recruit Count
- 10
- Registration Number
- NCT00825188
- Locations
- 🇺🇸
The University of Mississippi Clinical Research Program, Jackson, Mississippi, United States
A Study to Compare the Efficacy, Safety and Tolerability of Selomax With Its Individual Components
- First Posted Date
- 2009-01-08
- Last Posted Date
- 2009-09-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 402
- Registration Number
- NCT00819104
- Locations
- 🇮🇳
Research Site, Delhi, India
Direct Renin Inhibition Effects on Atherosclerotic Biomarkers
- Conditions
- Interventions
- First Posted Date
- 2009-01-08
- Last Posted Date
- 2017-12-05
- Lead Sponsor
- Texas Tech University Health Sciences Center
- Target Recruit Count
- 38
- Registration Number
- NCT00818779
- Locations
- 🇺🇸
Texas Tech University Health Sciences Center, Lubbock, Texas, United States
Aliskiren and the Calcium Channel Blocker Amlodipine Combination as an Initial Treatment Strategy for Hypertension
- Conditions
- Interventions
- First Posted Date
- 2008-11-25
- Last Posted Date
- 2011-10-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1254
- Registration Number
- NCT00797862
- Locations
- 🇻🇪
Investigative Site, Caracas, Venezuela
Aliskiren HCTZ Compared to Amlodipine in Patients With Stage 2 Systolic Hypertension and Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2008-11-07
- Last Posted Date
- 2016-10-27
- Lead Sponsor
- Novartis
- Target Recruit Count
- 860
- Registration Number
- NCT00787605
- Locations
- 🇺🇸
Sites in USA, East Hanover, New Jersey, United States
Study to Evaluate the Efficacy and Safety of Combination Aliskiren/Amlodipine in Patients With Hypertension Not Adequately Responding to Amlodipine Alone
- Conditions
- Interventions
- First Posted Date
- 2008-10-24
- Last Posted Date
- 2016-10-27
- Lead Sponsor
- Novartis
- Target Recruit Count
- 847
- Registration Number
- NCT00778921
- Locations
- 🇹🇷
Investigative Site, Ankara, Turkey
Efficacy and Tolerability of an Aliskiren-based Treatment Algorithm in Patients With Mild to Moderate Hypertension
- Conditions
- Interventions
- First Posted Date
- 2008-10-03
- Last Posted Date
- 2020-08-06
- Lead Sponsor
- Novartis
- Target Recruit Count
- 256
- Registration Number
- NCT00765947
- Locations
- 🇸🇰
Investigative Site, Bratislava, Slovakia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.